Search | Clinical Trials Finder

Conditions: Urge Urinary Incontinence
Interventions: Solifenacin; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Detrusor Overactivity, Overactive Bladder
Interventions: Placebo, solifenacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 547 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: New York, New York • West Reading, Pennsylvania

Conditions: Urinary Bladder Overactive, Overactive Bladder, Urgency Incontinence, Urinary Bladder Diseases\Urologic Diseases
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 1,829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 75
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 61 more

Conditions: Overactive Bladder
Interventions: PTNS plus solifenacin, Placebo; Other
Lead sponsor: Bay State Clinical Trials, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Watertown, Massachusetts

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin Succinate Suspension, Placebo, Urotherapy; Drug · Behavioral
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Albany, New York

Conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more

Conditions: Overactive Bladder, Urinary Incontinence
Interventions: BOTOX®, solifenacin, Botox placebo (normal saline), solifenacin placebo; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Overactive Bladder
Interventions: Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification; Drug · Behavioral
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Neurogenic Detrusor Overactivity
Interventions: Solifenacin succinate; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Tarrytown, New York • Cincinnati, Ohio

Conditions: Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases
Interventions: mirabegron 25 mg, mirabegron 50 mg, solifenacin 5 mg, solifenacin 10 mg, mirabegron 25 mg matching placebo, mirabegron 50 mg matching placebo, solifenacin 5 mg matching placebo, solifenacin 10 mg matching placebo; Drug
Lead sponsor: Astellas Pharma Europe Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 2,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 36
States / cities: Tucson, Arizona • Buena Park, California • Los Angeles, California + 31 more

Conditions: Lower Urinary Tract Symptoms
Interventions: Tamsulosin, Solifenacin; Drug
Lead sponsor: Timothy Boone, MD, PhD; Other
Eligibility: 45 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Urinary Frequency, Urinary Urgency, Nocturia
Interventions: Solifenacin PO; Drug
Lead sponsor: Seattle Urology Research Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Overactive Bladder, Dementia, Lower Urinary Tract Symptoms, Incontinence, Urge
Interventions: Anticholinergic, Beta-3 Agonists, Adrenergic, Functional magnetic resonance imaging (fMRI), Rey Auditory Verbal Learning Test (RAVLT); Drug · Diagnostic Test
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Houston, Texas • Temple, Texas

Conditions: Overactive Bladder
Interventions: Solifenacin; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years to 89 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Pelvic Organ Prolapse
Interventions: Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex; Drug · Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Urinary Incontinence, Parkinson's Disease
Interventions: Solifenacin Succinate (VESIcare), Placebo; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 30 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Urinary Incontinence
Interventions: solifenacin succinate, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 58
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 53 more

Conditions: Urinary Incontinence
Interventions: Vesicare; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Orange, California

Conditions: Urge Urinary Incontinence, Overactive Bladder
Interventions: Botulinum toxin A (Botox A®), Solifenacin 5mg, Solifenacin 10mg, Trospium chloride; Drug
Lead sponsor: NICHD Pelvic Floor Disorders Network; Network
Eligibility: 21 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • San Diego, California + 8 more

Search by objective public record fields.

Incontinence & Intimate Partners: Assessing the Contribution of Treatment

Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder

Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Bacterial Genomic Sequencing in Overactive Bladder

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease

A Study to Assess Efficacy and Safety With Solifenacin Succinate to Improve Urinary Continence After Robotic Assisted Radical Prostatectomy

Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)

Anticholinergic vs. Botox Comparison Study